Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection

Inclusion Criteria: * Male and Female subjects, 18-65 years of age (females non-child bearing potential in Part B) * Have laboratory evidence of HCV infection for 6 months, defined by (1) presence of anti-HCV antibody (Genotype 1a and 1b infection), or (2)documented HCV RNA presence by a sensitive and specific assay and (3 histologic evidence of CHC (Fibrosis on a standardized histological grading system) * Plasma HCV RNA of 100,000 IU/ml * HIV 1 and HIV2 ab seronegative * Body Mass Index (BMI) ≤ 35 kg/m2 BMI * Treatment Naive subjects Exclusion Criteria: * Contraindications to peginterferon or ribavirin therapy * Have evidence of liver cirrhosis, decompensated liver disease, and Child-Pugh score \> 5 * Have hemoglobinopathies, unstable cardiac disease, history of organ transplant, active malignant disease or uncontrolled Type I or II diabetes